MENTR Implant
MENT Acetate Implant, 7alpha-Methyl-19-Nortestosterone, MENTR
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Population Council
Details
- API: 7alpha-Methyl-19-Nortestosterone
- Target: Androgen Receptor
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: Elastomer, EVA
- Regimen: 2-4 Implants (Simultaneous)/12 Months
- MPT: Not Potential MPT
- Promising Attributes: MENT is more potent than testosterone and is resistant to 5 alpha-reduction. Long-acting implants improve compliance and efficacy.
Product Status
Developer Confirms Product is Inactive
History
Population Council and the University of Helsinki have evaluated 7 alpha-methyl-19-nortestosterone (MENT) for use in a long-acting contraceptive implant for male users since at least 1993. 2003 clinical trial results indicated that implants containing MENT acetate could inhibit sperm production over a long duration. Population Council has also evaluated MENT in combination with etonogestrel and levonorgestrel. In 2023, Population Council affirmed their continued interest in the development of a MENT implant, among other male methods.